Familieplanlegging, graviditet og amming ved multippel sklerose

Holmøy, Trygve; Torkildsen, Øivind

doi:10.4045/tidsskr.16.0563

Cited by 6 publications

(6 citation statements)

References 32 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Glatirameracetat og interferon-β er store molekyler som denatureres i gastrointestinalkanalen. Disse har derfor tradisjonelt vaert regnet som de tryggeste MSmedikamentene å bruke under ammeperioden (1). Nye sikkerhets-og oppfølgingsdata fra barn bekrefter at amming er trygt under behandling med disse preparatene (5).…”

Section: Injeksjonspreparaterunclassified

“…A akkbehandling MS-a akker behandles typisk med høydose steroider. Vi har tidligere advart mot steroidbehandling hos ammende kvinner (1). Nyere studier har imidlertid vist at overgangen til morsmelk er lav, og barnet eksponeres bare for 0,50 % av dosen mor mo ar (11).…”

Section: A L E Mt Uzum a Bunclassified

“…Illustrasjon: Isabel Albertos I 2016 publiserte vi en oversiktsartikkel om behandling av multippel sklerose (MS) ved graviditet og amming (1). Amming gir mange helsefordeler for mor og barn og er assosiert med lavere risiko for postpartuma akker hos kvinner som har multippel sklerose (2).…”

unclassified

See 2 more Smart Citations

Breastfeeding and treatment for multiple sclerosis

Torkildsen¹,

Rød²,

Liu³

et al. 2022

Tidsskriftet

View full text Add to dashboard Cite

Øivind Torkildsen er professor og seksjonsleder for Nevroseksjonen, Universitetet i Bergen, overlege ved Nevrologisk avdeling, Haukeland universitetssjukehus og medlem av referansegruppen til Nasjonal kompetansetjeneste for multippel sklerose. Forfa eren har fylt ut ICMJE-skjemaet og oppgir følgende interessekonflikter: Han har mo a foredragshonorar og forskningsstø e fra Biogen, Roche, Novartis, Merck og Sanofi. Brit Ellen Rød er lege i spesialisering i nevrologi ved Nevrologisk avdeling, Haukeland universitetssjukehus og stipendiat ved Universitetet i Bergen. Forfa eren har fylt ut ICMJE-skjemaet og oppgir ingen interessekonflikter. Lars Bø er overlege ved Nevrologisk avdeling, Haukeland universitetssjukehus, professor ved Universitetet i Bergen og leder for Nasjonal kompetansetjeneste for multippel sklerose. Forfa eren har fylt ut ICMJE-skjemaet og oppgir følgende interessekonflikter: Han har mo a foredragshonorar fra Merck og honorar for arbeid som sakkyndig fra Synthon. Stig Wergeland er medisinsk leder av Nasjonalt MS-register, overlege ved Nevrologisk avdeling, Haukeland universitetssjukehus og førsteamanuensis ved Universitetet i Bergen. Forfa eren har fylt ut ICMJE-skjemaet og oppgir følgende interessekonflikter: Han har mo a honorar fra Biogen, Novartis og Sanofi.

show abstract

Section: Injeksjonspreparaterunclassified

Section: A L E Mt Uzum a Bunclassified

See 1 more Smart Citation

Breastfeeding and treatment for multiple sclerosis

Torkildsen¹,

Rød²,

Liu³

et al. 2022

Tidsskriftet

View full text Add to dashboard Cite

show abstract

“…Table 2 summarizes reported effects of DMTs on fertility with special concerns to the following DMTs: interferon beta [30], natalizumab [31], alemtuzumab [17], mitoxantrone [31], and cyclophosphamide [31]. An additional concern exists for autologous stem cell transplant in combination with high-dose chemotherapy, which is an experimental MS treatment and may decrease fertility [32].…”

Section: Pre-pregnancymentioning

confidence: 99%

Women’s Health: Contemporary Management of MS in Pregnancy and Post-Partum

Tisovic

Amezcua

2019

Biomedicines

View full text Add to dashboard Cite

Multiple sclerosis (MS) primarily affects women in childbearing age and is associated with an increased risk of adverse post-partum outcomes. Relapses and now fetal exposure to disease modifying treatments in the early phase of pregnancy and thereafter are of concern. Safe and effective contraception is required for women who wish to delay or avoid pregnancy while on disease-modifying treatments. Counseling and planning is essential to assess the risk of both fetal and maternal complications, particularly now in the era of highly efficient and riskier therapies. The purpose of this review is to provide a practical framework using the available data surrounding pregnancy in MS with the goal of optimizing outcomes during this phase in MS.

show abstract

“…MS relapses during pregnancy are rare, but they frequently occur in the postpartum period [4]. The first three months of postpartum are considered a high-risk period for increased clinical and MRI disease activity, then returning to the pre-pregnancy level.…”

Section: Introductionmentioning

confidence: 99%

The Effect of Multiple Sclerosis on Family Planning Among Saudi Families

Albahrani,

Al Amer,

AlSahaf

et al. 2023

Cureus

View full text Add to dashboard Cite

BackgroundMultiple sclerosis (MS) is one of the most common neurological disorders in the world, and it is the leading cause of non-traumatic disability among young adults. While genetic susceptibility plays a role in MS development, the condition is not directly hereditary. Nevertheless, MS tends to aggregate within families, with first-degree relatives of affected individuals facing a higher risk than the general population. Additionally, family planning knowledge is insufficient among MS patients. Hence, this study aimed to assess the influence of MS disease on family planning and define the factors influencing decision-making regarding family planning in multiple sclerosis patients in the Eastern province of Saudi Arabia. MethodologyA prospective study was conducted in Eastern Province, Saudi Arabia, during the period of 2022-2023 through directly interviewing the patients using a pre-validated questionnaire. This study would improve counseling and future care plans regarding family planning during patients' visits. ResultsA total of 57 women with MS were enrolled in this study; 35 (61.4%) patients got pregnant after the onset of the disease, and 46 (97.9%) had healthy children. A total of 23 (40.4%) were previously aborted due to the disease. Only five (8.8%) diseased women experienced relapses of the disease during previous pregnancies. A total of 14 (24.6%) women reported that generally their condition improved during pregnancy and childbirth, and 12 (21.1%) had no change, while four (7%) reported that their condition generally deteriorated. Also, 15 (26.3%) had no change in their condition during the first three months after birth, while four (7%) experienced deteriorated condition. Exactly 71.2% reported that the disease mostly affected their planning for pregnancy, which was of greater extent among 24.6% and partial among 14%. ConclusionMultiple sclerosis affects women's decisions regarding family planning. The most reported causes among affected women included anxiety about weakness and lack of strength during childbirth, concern about possible side effects from MS drugs on the fetus (congenital malformations), worry about not being able to take care of a child due to illness and the severe impact of the disease on their health.

show abstract

Familieplanlegging, graviditet og amming ved multippel sklerose

Cited by 6 publications

References 32 publications

Breastfeeding and treatment for multiple sclerosis

Breastfeeding and treatment for multiple sclerosis

Women’s Health: Contemporary Management of MS in Pregnancy and Post-Partum

The Effect of Multiple Sclerosis on Family Planning Among Saudi Families

Contact Info

Product

Resources

About